We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PRPO Stock Slips Post Q3 Earnings Despite Revenue and Product Growth
Read MoreHide Full Article
Shares of Precipio, Inc. (PRPO - Free Report) have lost 0.3% since the company reported its earnings for the third quarter ended Sept. 30, 2026, underperforming the S&P 500 Index’s 0.3% gain over the same period. Over the past month, PRPO shares gained 1.1%, outperforming the benchmark index’s 2.3% decline.
Precipio’s Earnings Snapshot
Precipio reported third-quarter 2026 revenues of $7.3 million, up 8.3% year over year from $6.8 million. The company reported a nearly break-even result, with a net loss of $8,000 compared with $79,000 a year earlier. PRPO reported a nominal loss per share compared with a loss of 5 cents per share in the year-ago quarter.
Pathology revenues increased 5% year over year to $6.3 million from $6 million, while product revenues surged 40% to $1 million from $0.7 million. Precipio operates as a single reporting segment comprising these two divisions.
PRPO's Key Metrics
Gross profit increased 12.4% to $3.4 million from $3 million in the year-ago quarter. Gross margin expanded to 46% from 44%, reflecting higher revenues and improved operating leverage.
Adjusted EBITDA declined to $0.4 million from $0.5 million in the prior-year period, despite improving operating performance.
Operating expenses increased 10.1% to $3.4 million from $3.1 million, primarily reflecting higher personnel costs and legal and professional fees.
During the quarter, PRPO processed 4,582 diagnostic cases, up 7.6% from 4,258 cases a year earlier. However, a less favorable case mix reduced average revenue per case, partially offsetting volume growth.
Product revenue growth was primarily driven by revenues from new product-related projects and activities outside PRPO’s historical product sales.
Precipio generated operating cash flow of approximately $0.6 million during the third quarter, compared with $0.7 million in the preceding quarter.
Cash and cash equivalents increased to $3.6 million as of Sept. 30, 2026, from $2.7 million as of Dec. 31, 2025.
Total assets were $21.7 million compared with $21.3 million as of Dec. 31, 2025. Total liabilities increased to $6.85 million from $6.76 million on a rounded basis.
Despite improving liquidity, Precipio continued to express substantial doubt about its ability to remain a going concern over the following 12 months, reflecting historical operating losses and dependence on executing its growth strategy.
PRPO's Management Commentary
CEO Ilan Danieli highlighted PRPO's transition from achieving financial stability toward accelerating revenue growth.
Management emphasized its distribution partnerships with Thermo Fisher, Medline, McKesson and Cardinal Health as important channels for expanding product commercialization.
Precipio plans to double its sales force from four representatives in 2027, supported by additional marketing and technical resources.
Chief operating officer Zaki Sabet highlighted PRPO's existing infrastructure, which management estimates could support approximately $100 million in annual revenues without significant additional investment in core facilities and equipment.
However, customer onboarding remains challenging, with implementation timelines potentially extending from three to 18 months.
Precipio’s 2027 Outlook
Precipio targets an annualized product revenue run rate exceeding $10 million by the end of 2027, compared with approximately $4 million based on third-quarter 2026 results.
PRPO also aims to achieve an annualized pathology revenue run rate of approximately $30 million, bringing its combined exit run-rate target above $40 million.
Management clarified that these objectives represent targeted annualized revenue levels exiting 2027 rather than expected full-year reported revenues.
Achieving these targets will depend on customer conversions, successful sales force expansion and effective distributor engagement.
PRPO's Other Developments
Following the third quarter of 2026, Precipio implemented changes to its commercial leadership and began coordinating product and pathology sales efforts under a more unified structure.
The initiative is intended to improve customer engagement, strengthen commercial execution and support PRPO's accelerated growth strategy for 2027.
Image: Bigstock
PRPO Stock Slips Post Q3 Earnings Despite Revenue and Product Growth
Shares of Precipio, Inc. (PRPO - Free Report) have lost 0.3% since the company reported its earnings for the third quarter ended Sept. 30, 2026, underperforming the S&P 500 Index’s 0.3% gain over the same period. Over the past month, PRPO shares gained 1.1%, outperforming the benchmark index’s 2.3% decline.
Precipio’s Earnings Snapshot
Precipio reported third-quarter 2026 revenues of $7.3 million, up 8.3% year over year from $6.8 million. The company reported a nearly break-even result, with a net loss of $8,000 compared with $79,000 a year earlier. PRPO reported a nominal loss per share compared with a loss of 5 cents per share in the year-ago quarter.
Pathology revenues increased 5% year over year to $6.3 million from $6 million, while product revenues surged 40% to $1 million from $0.7 million. Precipio operates as a single reporting segment comprising these two divisions.
PRPO's Key Metrics
Gross profit increased 12.4% to $3.4 million from $3 million in the year-ago quarter. Gross margin expanded to 46% from 44%, reflecting higher revenues and improved operating leverage.
Adjusted EBITDA declined to $0.4 million from $0.5 million in the prior-year period, despite improving operating performance.
Operating expenses increased 10.1% to $3.4 million from $3.1 million, primarily reflecting higher personnel costs and legal and professional fees.
During the quarter, PRPO processed 4,582 diagnostic cases, up 7.6% from 4,258 cases a year earlier. However, a less favorable case mix reduced average revenue per case, partially offsetting volume growth.
Product revenue growth was primarily driven by revenues from new product-related projects and activities outside PRPO’s historical product sales.
Precipio, Inc. Price, Consensus and EPS Surprise
Precipio, Inc. price-consensus-eps-surprise-chart | Precipio, Inc. Quote
Precipio’s Cash Flow and Liquidity
Precipio generated operating cash flow of approximately $0.6 million during the third quarter, compared with $0.7 million in the preceding quarter.
Cash and cash equivalents increased to $3.6 million as of Sept. 30, 2026, from $2.7 million as of Dec. 31, 2025.
Total assets were $21.7 million compared with $21.3 million as of Dec. 31, 2025. Total liabilities increased to $6.85 million from $6.76 million on a rounded basis.
Despite improving liquidity, Precipio continued to express substantial doubt about its ability to remain a going concern over the following 12 months, reflecting historical operating losses and dependence on executing its growth strategy.
PRPO's Management Commentary
CEO Ilan Danieli highlighted PRPO's transition from achieving financial stability toward accelerating revenue growth.
Management emphasized its distribution partnerships with Thermo Fisher, Medline, McKesson and Cardinal Health as important channels for expanding product commercialization.
Precipio plans to double its sales force from four representatives in 2027, supported by additional marketing and technical resources.
Chief operating officer Zaki Sabet highlighted PRPO's existing infrastructure, which management estimates could support approximately $100 million in annual revenues without significant additional investment in core facilities and equipment.
However, customer onboarding remains challenging, with implementation timelines potentially extending from three to 18 months.
Precipio’s 2027 Outlook
Precipio targets an annualized product revenue run rate exceeding $10 million by the end of 2027, compared with approximately $4 million based on third-quarter 2026 results.
PRPO also aims to achieve an annualized pathology revenue run rate of approximately $30 million, bringing its combined exit run-rate target above $40 million.
Management clarified that these objectives represent targeted annualized revenue levels exiting 2027 rather than expected full-year reported revenues.
Achieving these targets will depend on customer conversions, successful sales force expansion and effective distributor engagement.
PRPO's Other Developments
Following the third quarter of 2026, Precipio implemented changes to its commercial leadership and began coordinating product and pathology sales efforts under a more unified structure.
The initiative is intended to improve customer engagement, strengthen commercial execution and support PRPO's accelerated growth strategy for 2027.